Search details
1.
Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study.
Br J Haematol
; 204(4): 1293-1299, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38263627
2.
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.
Br J Haematol
; 2024 Mar 19.
Article
in English
| MEDLINE | ID: mdl-38504552
3.
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.
Haematologica
; 109(3): 777-786, 2024 Mar 01.
Article
in English
| MEDLINE | ID: mdl-37731379
4.
Comparison of biosimilar filgrastim and originator filgrastim for peripheral blood stem cell mobilization for allogeneic hematopoietic stem cell transplantation.
Transfusion
; 2024 Jun 07.
Article
in English
| MEDLINE | ID: mdl-38847196
5.
Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias.
Eur J Haematol
; 112(4): 538-546, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38044594
6.
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunotherapy Consortium real world experience.
Haematologica
; 2023 10 19.
Article
in English
| MEDLINE | ID: mdl-37855036
7.
Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma.
Eur J Haematol
; 110(6): 626-632, 2023 Jun.
Article
in English
| MEDLINE | ID: mdl-36752328
8.
Neutralizing antibody responses against SARS-CoV-2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination.
Eur J Haematol
; 109(5): 458-464, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-35810359
9.
Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma.
Eur J Haematol
; 109(5): 559-565, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-36054450
10.
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study.
Future Oncol
; 18(40): 4443-4456, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-36799429
11.
Hospitalization at the end of life in patients with multiple myeloma.
BMC Cancer
; 21(1): 339, 2021 Mar 31.
Article
in English
| MEDLINE | ID: mdl-33789626
12.
Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019.
BMC Cancer
; 21(1): 730, 2021 Jun 26.
Article
in English
| MEDLINE | ID: mdl-34172037
13.
Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM).
Eur J Haematol
; 107(6): 602-608, 2021 Dec.
Article
in English
| MEDLINE | ID: mdl-34378251
14.
Inpatient mortality of patients with multiple myeloma and renal impairment undergoing autologous stem cell transplantation.
Eur J Haematol
; 105(5): 571-577, 2020 Nov.
Article
in English
| MEDLINE | ID: mdl-32662224
15.
Results of the First Clinical Study in Humans That Combines Hyperbaric Oxygen Pretreatment with Autologous Peripheral Blood Stem Cell Transplantation.
Biol Blood Marrow Transplant
; 25(9): 1713-1719, 2019 09.
Article
in English
| MEDLINE | ID: mdl-31170519
16.
Long-term results of a pilot study evaluating hyperbaric oxygen therapy to improve umbilical cord blood engraftment.
Ann Hematol
; 98(2): 481-489, 2019 Feb.
Article
in English
| MEDLINE | ID: mdl-30382305
17.
Erythropoietin modulation is associated with improved homing and engraftment after umbilical cord blood transplantation.
Blood
; 128(25): 3000-3010, 2016 12 22.
Article
in English
| MEDLINE | ID: mdl-27760758
18.
Utility of Routine Surveillance Imaging for Hodgkin Disease following Autologous Transplant: Experiences from a Single Institution.
Acta Haematol
; 139(1): 52-57, 2018.
Article
in English
| MEDLINE | ID: mdl-29339629
19.
Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple Myeloma Undergoing Outpatient Autologous Stem Cell Transplantation.
Biol Blood Marrow Transplant
; 23(10): 1641-1645, 2017 Oct.
Article
in English
| MEDLINE | ID: mdl-28603071
20.
Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome.
Biol Blood Marrow Transplant
; 21(5): 866-72, 2015 May.
Article
in English
| MEDLINE | ID: mdl-25620751